Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.
about
Hepatitis C virus relies on lipoproteins for its life cycleChronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective.Hepatitis C and insulin action: An intimate relationshipState of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and ImmunizationHepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in EuropeGenotype Distribution and Molecular Epidemiology of Hepatitis C Virus in Hubei, Central ChinaRecent Advances in Application of Pharmacogenomics for BiotherapeuticsHigh Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms.Estimating the Impact of Expanding Treatment Coverage and Allocation Strategies for Chronic Hepatitis C in a Direct Antiviral Agent EraPrevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallateA randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3.Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection.Aptamers against pathogenic microorganisms.Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000-2015 period (the GEHEP 005 study).During Hepatitis C Virus (HCV) Infection and HCV-HIV Coinfection, an Elevated Plasma Level of Autotaxin Is Associated With Lysophosphatidic Acid and Markers of Immune Activation That Normalize During Interferon-Free HCV Therapy.Peginterferon Alfa-2a/Ribavirin treatment efficacy in chronic hepatitis C patients is related to natural killer group 2D gene rs1049174 GC polymorphism.The lipid droplet-associated protein perilipin 3 facilitates hepatitis C virus-driven hepatic steatosis."Hep C, where art thou": What are the remaining (fundable) questions in hepatitis C virus research?Bilateral simultaneous anterior ischemic optic neuropathy, an extrahepatic manifestation of hepatitis C cured with direct acting antivirals.Fibrosis is not just fibrosis - basement membrane modelling and collagen metabolism differs between hepatitis B- and C-induced injury.Temporal dynamics of hepatitis C genotypes in a five-year hospital-based surveillance in Northern Italy.United Kingdom National Guideline on the Management of the viral hepatitides A, B and C 2015.Detection of Hepatitis C Virus RNA in Blood and Saliva of Transfusion-Dependent Thalassemia Patients Diagnosed with Hepatitis C.Acute Kidney Injury in Patients Undergoing Chronic Hepatitis C Virus Treatment With Ledipasvir/SofosbuvirHepatitis C in Lebanon: the burden of the disease and the value of comprehensive screening and treatmentSoluble Markers of Immune Activation Differentially Normalize and Selectively Associate with Improvement in AST, ALT, Albumin, and Transient Elastography During IFN-Free HCV TherapyA very high prevalence of hepatitis C virus infection among patients undergoing hemodialysis in Kosovo: a nationwide study
P2860
Q26766119-DC64C565-6DD7-440C-B757-91375215B0EFQ26773585-DFA30D9A-2A2E-43E9-947D-3CDFD9BEAD1DQ26775000-C4CD2F92-5474-4CF2-9876-393E9CFC0F8EQ28079102-881693F2-7F57-4398-8173-A7607F0DB4DCQ28079580-02382448-1BEF-4CE8-8CE7-0770DD17713FQ28547657-46D6A8AA-FA56-416E-86E6-F18D888B2561Q29247996-65A8154D-CB1E-426B-8047-22BD1BFE9536Q35907984-1DB8382F-2203-4B4A-8C56-DF6AAFE0FE66Q36133794-22FCBB45-F1FA-41FE-9634-9F70048F165DQ36624431-569E2D05-8240-4593-9DAC-C5F00E6074C8Q37187994-D20ADBB6-F77A-4310-A71A-366C445923A9Q38344512-E9A20660-616B-4908-AD3E-3C1F146BA4F3Q38563672-9C9E13C5-576D-4330-81B0-52A64976DF4BQ38935930-0FBCE73B-E61C-429F-B05D-70C7A1B3AA9DQ39475044-FC810B2E-CAC2-4585-8B4F-3458BDC24C55Q40399586-AFDEDB24-7675-426B-9764-F7E46DA1C7E3Q40414261-8AC71B0A-5BA4-4071-9E68-01F9113BCA51Q40536482-99D9E86B-08E8-44D7-A7E0-3AA72E18D92FQ40541037-6AD31601-40ED-4BDF-AC03-19B9507598F5Q40556586-7B0400F5-3B4A-48EB-8209-DDF513BFDF3CQ40611739-AB71B10B-0BDC-40B8-A2DD-0835FFBA2DB4Q40990518-1036C1E3-180D-483E-8618-857687A7DAA7Q55160157-B09AB8EE-388C-409B-883A-185B193F3732Q57070331-ADA39F2D-4FF1-4C38-AAE8-A459B88102B3Q57167190-1F5FC201-4013-46BE-83D8-6B31A4729830Q58127297-102DCC7B-5029-4CD1-856A-981AF212BAB4Q58613690-6AD20FF5-3400-4B96-9015-3798BF96A8E3
P2860
Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Hepatitis C virus in the new e ...... ictors of response to therapy.
@ast
Hepatitis C virus in the new e ...... ictors of response to therapy.
@en
Hepatitis C virus in the new e ...... ictors of response to therapy.
@nl
type
label
Hepatitis C virus in the new e ...... ictors of response to therapy.
@ast
Hepatitis C virus in the new e ...... ictors of response to therapy.
@en
Hepatitis C virus in the new e ...... ictors of response to therapy.
@nl
prefLabel
Hepatitis C virus in the new e ...... ictors of response to therapy.
@ast
Hepatitis C virus in the new e ...... ictors of response to therapy.
@en
Hepatitis C virus in the new e ...... ictors of response to therapy.
@nl
P2093
P2860
P356
P1476
Hepatitis C virus in the new e ...... ictors of response to therapy.
@en
P2093
Andrea Orsi
Bianca Bruzzone
Filippo Ansaldi
Giancarlo Icardi
Laura Sticchi
P2860
P304
P356
10.3748/WJG.V20.I29.9633
P407
P577
2014-08-01T00:00:00Z